Glaukos Co. (NYSE:GKOS) Shares Acquired by Creative Planning

Creative Planning boosted its position in shares of Glaukos Co. (NYSE:GKOS) by 126.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,706 shares of the medical instruments supplier’s stock after purchasing an additional 4,309 shares during the period. Creative Planning’s holdings in Glaukos were worth $912,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Fisher Asset Management LLC acquired a new position in Glaukos during the 4th quarter worth $216,000. Nomura Holdings Inc. grew its holdings in Glaukos by 3.2% during the 4th quarter. Nomura Holdings Inc. now owns 232,034 shares of the medical instruments supplier’s stock worth $18,444,000 after acquiring an additional 7,146 shares in the last quarter. SteelPeak Wealth LLC acquired a new position in Glaukos during the 1st quarter worth $343,000. Allspring Global Investments Holdings LLC grew its holdings in Glaukos by 127.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 166,054 shares of the medical instruments supplier’s stock worth $15,657,000 after acquiring an additional 93,076 shares in the last quarter. Finally, Caldwell Sutter Capital Inc. grew its holdings in Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after acquiring an additional 1,465 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Glaukos

In other news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total transaction of $646,800.00. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $13,216,581.84. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,250 shares of company stock valued at $4,825,873. 6.40% of the stock is owned by insiders.

Glaukos Trading Down 1.0 %

Shares of Glaukos stock opened at $126.90 on Friday. The firm has a market capitalization of $6.97 billion, a PE ratio of -38.93 and a beta of 1.02. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67. The company’s fifty day moving average price is $127.11 and its two-hundred day moving average price is $115.64. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $136.60.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.55) EPS. On average, analysts expect that Glaukos Co. will post -2.18 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Truist Financial reissued a “buy” rating and set a $145.00 price objective (up from $141.00) on shares of Glaukos in a report on Thursday, August 1st. Citigroup lowered shares of Glaukos from a “buy” rating to a “neutral” rating and lifted their price target for the company from $130.00 to $132.00 in a report on Wednesday, July 10th. Stifel Nicolaus lifted their price target on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Piper Sandler lifted their price target on shares of Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a report on Friday, August 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and an average price target of $129.82.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.